This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain Stock Options of Precision BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI
Certain Common Stock of Precision BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, vs. Street Est of $6.02M MT
Precision BioSciences, Inc. announced that it has received $0.3 million in funding CI
Guggenheim Starts Precision BioSciences With Buy Rating, $19 Price Target MT
Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration MT
Transcript : Precision BioSciences, Inc. - Special Call
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics CI
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M MT
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency CI
Precision BioSciences Launches $40 Million Public Offering; Shares Slump MT
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences CI
Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness CI
Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc. CI
Precision BioSciences Announces 1-for-30 Reverse Stock Split; Shares Fall MT
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program MT
TG Therapeutics, Inc. Announces Global License Agreement with Precision BioSciences, Inc. for the Development and Commercialization of Precision?s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases CI
Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure CI
Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases CI
Transcript : Precision BioSciences, Inc. - Special Call
Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD?s The Liver Meeting 2023 CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q3 Revenue $13.1M MT
Chart Precision BioSciences, Inc.
More charts
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.82 USD
Average target price
33 USD
Spread / Average Target
+157.41%
Consensus
  1. Stock Market
  2. Equities
  3. DTIL Stock
  4. News Precision BioSciences, Inc.
  5. BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7